Blocknomi
TLDR AbbVie closes $10.9B Apogee deal and expands its immunology treatment pipeline. ABBV stock rises as Apogee adds key programs targeting dermatitis and asthma. Zumilokibart becomes a major new asset…
Related articles
-
ARB Skyrockets by Double Digits Again, BTC Recovers From Drop to $76K: Market Watch
CryptoPotato Published 03.09.2026 09:28
-
Tom Lee Says Avoid Crypto Favorite Robinhood Stock Despite Record Q2 Growth
BeInCrypto Published 19.08.2026 22:44
-
Nvidia (NVDA) Stock Pursues $20B Investment in AI Data Company Mercor
Blocknomi Published 20.08.2026 08:30
-
Pyth Network’s API overhaul threatens to freeze unpatched smart contracts across 300 DeFi protocols
CryptoSlate Published 27.08.2026 08:10
-
Coldcard now requires 65 key presses after seed exploit, while exposed funds still must move
CryptoSlate Published 23.08.2026 05:00
-
Morning Minute: Solana Jumps with Network Inflation Set to Drop
Decrypt Published 28.08.2026 12:13
-
Roman Storm Won’t Face a Tornado Cash Retrial Until 2027
BeInCrypto Published 26.08.2026 12:24
-
Tron Surpasses 400 Million Accounts as USDT Transfers Near $30 Trillion
Bitcoin.com Published 26.08.2026 07:30